Quarterly report pursuant to Section 13 or 15(d)

Accrued Liabilities and other Long-Term Liabilities (Details)

v3.19.2
Accrued Liabilities and other Long-Term Liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Accrued expenses:    
Professional fees $ 1,051 $ 1,434
Salaries, bonuses and related benefits 4,479 5,843
Research and development 3,527 3,805
Research and development - manufacturing 946 826
Research and development - clinical supplies 160 160
Research and development - license maintenance fees 409 519
Research and development - milestones 200 200
Dr. Falk Pharma milestone   300
Accrued royalties payable 1,641 1,108
Accrued coupon expense 981 838
Other 1,401 1,327
Total accrued expenses 14,795 16,360
Other long-term liabilities:    
Deferred rent and long-term lease abandonment charge 2,229 5,211
Total other long-term liabilities $ 2,229 $ 5,211